ArticleESMO real world data and digital oncology2026
X-CART: a multimodal real-world data pipeline for explainable AI-driven patient navigation in radiation oncology.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multimodal explainable artificial intelligence (XAI) is transforming oncology, yet its clinical adoption is constrained by limited interpretability and fragmented use of real-world data (RWD), including electronic medical records, geospatial data, and social determinants of health. We present the XAI CAncer Radiation Therapy (X-CART) platform, a multimodal RWD pipeline designed to enable explainable, clinically actionable precision oncology. Materials and methods: X-CART integrates heterogeneous RWD into a unified, AI-ready architecture for explainable radiotherapy interruption (RTI) risk prediction and patient navigation. A retrospective proof-of-implementation analysis demonstrated the pipeline's predictive modeling and explainability. This framework supports targeted, patient-level intervention strategies. Results: We developed a scalable, interoperable pipeline that synthesizes clinical and community-level data into a secure multimodal framework for RTI risk prediction and patient navigation. The system employs iterative machine learning with feedback-driven retraining and delivers real-time, interpretable outputs through an electronic medical record-embedded dashboard. The architecture is registry-extensible and aligned with interoperability standards to support multi-institutional deployment. As proof of implementation of the Data Science module, a retrospective cohort analysis including 2525 patients identified 622 RTI events (24.6%) and demonstrated modest discrimination with eXtreme Gradient Boosting on an independent hold-out test set (area under the receiver operating characteristic curve = 0.689) with cohort-level SHapley Additive exPlanations interpretability. Conclusion: The framework addresses critical RWD challenges, including data quality, completeness, and traceability. X-CART establishes a generalizable, privacy-preserving foundation for XAI in oncology and provides a practical blueprint for enriching cancer registries with multimodal RWD to support scalable, real-world evidence generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.